Opko Health Inc. (OPK) Expected to Announce Quarterly Sales of $254.10 Million

Analysts predict that Opko Health Inc. (NASDAQ:OPK) will announce sales of $254.10 million for the current quarter, Zacks reports. Three analysts have provided estimates for Opko Health’s earnings, with the highest sales estimate coming in at $267.50 million and the lowest estimate coming in at $239.10 million. Opko Health reported sales of $193.70 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 31.2%. The business is scheduled to report its next quarterly earnings results on Thursday, March 7th.

On average, analysts expect that Opko Health will report full-year sales of $1.03 billion for the current financial year, with estimates ranging from $1.01 billion to $1.05 billion. For the next year, analysts expect that the company will post sales of $1.05 billion, with estimates ranging from $1.03 billion to $1.09 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Opko Health.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03. Opko Health had a negative net margin of 30.24% and a negative return on equity of 8.68%. The firm had revenue of $250.00 million for the quarter, compared to analyst estimates of $264.04 million. During the same period in the prior year, the business posted ($0.08) EPS. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year.

Several equities analysts have recently commented on the stock. BidaskClub upgraded shares of Opko Health from a “buy” rating to a “strong-buy” rating in a report on Friday, August 3rd. Cantor Fitzgerald restated a “buy” rating and issued a $20.00 price objective on shares of Opko Health in a report on Tuesday, August 7th. ValuEngine upgraded shares of Opko Health from a “strong sell” rating to a “sell” rating in a report on Thursday, August 2nd. Finally, Barrington Research restated a “buy” rating and issued a $7.00 price objective on shares of Opko Health in a report on Monday, November 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $9.69.

In related news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the firm’s stock in a transaction dated Friday, September 7th. The shares were purchased at an average cost of $5.57 per share, for a total transaction of $55,700.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 42.74% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in OPK. RPg Family Wealth Advisory LLC increased its position in shares of Opko Health by 74.3% in the 2nd quarter. RPg Family Wealth Advisory LLC now owns 31,080 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 13,250 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Opko Health by 4.3% in the 3rd quarter. Wells Fargo & Company MN now owns 337,868 shares of the biotechnology company’s stock valued at $1,169,000 after purchasing an additional 13,905 shares during the last quarter. Strs Ohio increased its position in shares of Opko Health by 20.5% in the 3rd quarter. Strs Ohio now owns 88,600 shares of the biotechnology company’s stock valued at $306,000 after purchasing an additional 15,100 shares during the last quarter. RK Asset Management LLC increased its position in shares of Opko Health by 1.8% in the 3rd quarter. RK Asset Management LLC now owns 1,044,893 shares of the biotechnology company’s stock valued at $3,615,000 after purchasing an additional 18,875 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Opko Health by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 337,168 shares of the biotechnology company’s stock valued at $1,585,000 after purchasing an additional 19,316 shares during the last quarter. Institutional investors own 26.99% of the company’s stock.

Shares of OPK stock opened at $3.63 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.78 and a debt-to-equity ratio of 0.03. Opko Health has a one year low of $2.66 and a one year high of $6.40. The company has a market capitalization of $1.83 billion, a PE ratio of -12.52 and a beta of 1.89.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply